What are the management options for constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management Options for Constipation

The first-line treatment for constipation is polyethylene glycol (PEG) 3350 at a dosage of 17g dissolved in 8oz of water once daily, which has moderate certainty of evidence for effectiveness and a favorable safety profile. 1

Pharmacological Management

First-Line Options

  • Osmotic Laxatives
    • PEG 3350: 17g dissolved in 8oz water once daily; produces bowel movements within 1-3 days; safe for up to 12 months of continuous use 1
    • Lactulose: 15-30ml daily or twice daily as an alternative 1
    • Magnesium-based laxatives: Avoid in patients with renal insufficiency 1

Second-Line Options

  • Stimulant Laxatives
    • Senna (8.6-17.2mg) or bisacodyl (5-10mg) at bedtime 1
    • Particularly useful when osmotic laxatives alone are insufficient

For Opioid-Induced Constipation

  • Naldemedine: 0.2mg daily (strong evidence for achieving ≥3 spontaneous bowel movements/week) 1
  • Naloxegol: Recommended with moderate-quality evidence 1
  • Methylnaltrexone: 0.15mg/kg subcutaneously every other day (no more than once daily); useful when oral medications cannot be used 1
  • Lubiprostone: 24mcg twice daily with food; use with caution in patients taking methadone 1
  • Note: PAMORAs (peripherally acting mu-opioid receptor antagonists) are contraindicated in patients with gastrointestinal perforation risk or mechanical bowel obstruction 1

Novel Agents

  • Plecanatide: FDA-approved for chronic idiopathic constipation; acts as a guanylate cyclase-C agonist in the GI tract with minimal systemic absorption 2
    • Clinical trials showed 21% responder rate vs. 10-13% for placebo 2
    • Improvements in stool frequency and consistency observed as early as week 1 2

Lifestyle Modifications

Dietary Changes

  • Gradually increase dietary fiber to 20-25g per day, focusing on soluble fiber 1
  • Increase fluid intake to at least 8 glasses of water daily 1
  • Consider mineral water rich in magnesium and/or bicarbonate 3

Physical Activity

  • Increase physical activity within patient limits 1
  • Aim for at least 30 minutes of exercise per day to alleviate symptoms 4

Toileting Habits

  • Optimize toileting habits:
    • Ensure privacy and comfort
    • Use a footstool to elevate knees above hips
    • Establish a regular toileting schedule 1
    • Ensure access to toilets, especially for patients with decreased mobility 1

Assessment and Monitoring

Initial Evaluation

  • Evaluate for red flag symptoms:

    • Rectal bleeding
    • Unintentional weight loss
    • Change in stool caliber
    • Progressive abdominal pain 1
  • Physical examination:

    • Abdominal examination
    • Perineal inspection
    • Digital rectal examination to assess for fecal impaction 1

Monitoring Treatment Response

  • Reassess treatment efficacy within 2-4 weeks of initiating therapy 1
  • Goal: One non-forced bowel movement every 1-2 days 1
  • Use the Bowel Function Index to assess severity and monitor response:
    • Score ≥30 indicates clinically significant constipation requiring escalation of therapy 1

Special Situations

Fecal Impaction

  • Consider rectal interventions:
    • Glycerine suppositories
    • Rectal bisacodyl twice daily
    • Manual disimpaction if necessary 1

Types of Constipation and Specific Approaches

  • Slow Transit Constipation: May require laxative therapy beyond fiber and increased activity 5
  • Pelvic Floor Dysfunction/Dyssynergic Defecation: Biofeedback therapy and pelvic muscle re-education 5
  • Constipation-predominant IBS: Dietary monitoring and modifications, fiber therapy, and patient education 5

Important Caveats and Pitfalls

  • Docusate has not shown benefit and is not recommended 1
  • Using fiber supplements in patients with severe constipation or suspected obstruction is not recommended 1
  • Continuing ineffective treatments without reassessment is not recommended 1
  • Using PAMORAs as first-line treatment is not recommended 1
  • Common side effects of PEG include diarrhea, abdominal distension, flatulence, and nausea, which are typically mild to moderate 1
  • Bloating and flatulence are common side effects of highly fermentable fibers 4
  • Conservative treatment (lifestyle modifications alone) is usually insufficient and should be supplemented with laxatives or motility-enhancing drugs 4

References

Guideline

Constipation Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.